Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat.com Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthor: Nathan Reiff. Originally Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of biotechnology's greatest medical challenges, even as the oncology medicine market is expected to reach $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types using dedicated mechanisms. Several promising treatments have shown remarkable potential—and with that comes the possibility of significant revenue. Two smaller biotech firms are seeing notable share-price momentum thanks to their leading oncology medicines. Beyond their therapeutic potential, these drugs could help the companies move beyond penny-stock status and toward longer-term stability and profitability. That said, both remain typical biotech investments: high-risk ventures that could generate outsized rewards for investors willing to take the chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That gain added to a year-to-date rally that has more than doubled the stock so far. Still, with a consensus price target of $8.88, Wall Street appears to expect more—that target implies roughly 71% additional upside from current levels. The primary catalyst for Iovance's rally is its lead product, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi was approved in the U.S. in 2024 and is gaining momentum in sales, with potential approvals expected in the E.U., U.K., and other markets. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Its broader potential extends beyond melanoma: Amtagvi received FDA Fast Track designation for non-small cell lung cancer and may be active against other tumor types. Part of Iovance's strong performance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company reported narrower-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year over year. Iovance is a relatively small-cap company (about $2 billion), and despite the sizable rally, analysts remain cautious: roughly half of its dozen analyst ratings are Hold or Sell. Risks are significant. In addition to typical small-biotech risks, Iovance faces manufacturing challenges for Amtagvi—the therapy is personalized, expensive, and complex to produce—which could limit profitability even if demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year-to-date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026 alone. Analysts have set a price target of $13.60, roughly 70% above the stock's current level even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares rose after the EU regulator granted the drug conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva drove the firm's revenue to $113 million last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have indications beyond its current label; ImmunityBio is actively exploring additional tumor types and regulatory designations. Despite the rapid gains over recent quarters, IBRX remains speculative and risky. IBRX reported a net loss of $351 million for 2025 as R&D spending remains elevated. Wall Street analysts are relatively bullish, however: six of seven rate the stock a Buy or equivalent. | 
